Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01055067 · ClinicalTrials.gov registry record · Phase 2
ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors
A Phase 2 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01055067 is a Phase 2 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 27 participants.
The verdict
NCT01055067, a Phase 2 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a multicenter, single-arm study for safety and efficacy.
Interventions
- DRUG Tivantinib (ARQ 197)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-02-02 |
| Est. Completion | 2011-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01055067
The ClinicalTrials.gov registry entry for NCT01055067 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tivantinib (ARQ 197) is the first listed.
NCT01055067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01055067 about?
NCT01055067 is a clinical study titled "ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors". This is a multicenter, single-arm study for safety and efficacy.
What is the current status of trial NCT01055067?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2010-02-02. Estimated completion is 2011-11-30.
What interventions are being tested in trial NCT01055067?
The interventions under investigation include: Tivantinib (ARQ 197) (DRUG).
Who is sponsoring clinical trial NCT01055067?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.